WAS affects almost exclusively males, with an estimated incidence of 1 in 250,000 live male births. The therapy represents a major scientific and clinical achievement, offering new hope for patients affected by this condition. ROME, Italy, Dec. 10, 2025 /PRNewswire/ -- Fondazione Telethon...
Hence then, the article about fondazione telethon announces fda approval of waskyra etuvetidigene autotemcel a gene therapy for the treatment of wiskott aldrich syndrome was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Fondazione Telethon Announces FDA approval of Waskyra™ (etuvetidigene autotemcel), a Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome )
Also on site :
- Here’s What Jack Schlossberg Had to Say About Madonna’s Recent Revelations on JFK Jr. as a Lover: ‘All I Can Say Is…’
- ’90s Rock Band Extends 2026 Tour With Special Guests
- Sam Bankman-Fried formally files for pardon—but White House reiterates that FTX cofounder’s odds are slim